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Abstract Epigenetic mechanisms such as DNA hyperme-
thylation and modifications of histone amino acids are known
toplayanimportantroleinthecontrolofgeneexpressionboth
in normal human development and tumorigenesis. Hyper-
methylation of CpG islands within promoter regions of tumor
suppressor genes is associated with transcriptional inactiva-
tion and represents, in addition to genetic aberrations, an
important mechanism of gene silencing in the pathogenesis of
humancancer.Inter-α-trypsineinhibitors(ITIs)areafamilyof
serine protease inhibitors consisting of one light chain
(bikunin) and two heavy chains (ITI heavy chains, ITIHs).
ITIHs stabilize the extracellular matrix (ECM) by interacting
with hyaluronic acid, which is a major ECM component.
Hypermethylation in the upstream region of the promoter-
associated CpG island of ITIH5, the most recently described
member of the ITIH family, has been previously detected in
breast cancer and was associated with an adverse outcome. In
this study, we determined the DNA methylation status of the
promoter region near the transcription start site of the ITIH5
tumor suppressor gene in leukemia cell lines and primary
samples from patients with acute myeloid leukemia (AML) as
well as the potential use of demethylating agents to restore a
demethylated state of the promoter. Aberrant ITIH5 promoter
hypermethylation occurred in 15 of 104 (14.4%) diagnostic
AML samples. There were no statistically significant correla-
tions between the ITIH5 methylation status and clinical
prognostic parameters. Our results indicate that aberrant
ITIH5 promoter hypermethylation is a novel epigenetic event
in AML.
Keywords DNA hypermethylation.Epigenetics.Acute
myeloid leukemia.Inter-α-trypsine inhibitor.Tumor
suppressor gene
Introduction
The pathogenesis of human cancer is characterized by a
multistep process involving multiple molecular altera-
tions leading to dysregulation of a variety of signaling
pathways (Hanahan and Weinberg 2011). Acute myeloid
leukemia (AML) is a clonal disorder of hematopoietic
stem cells characterized by disrupted maturation and
uncontrolled proliferation of immature progenitor cells
and subsequent suppression of normal hematopoiesis
(Löwenberg et al. 1999). Normal hematopoietic stem cells
(HSC) are defined by their ability to exert self-renewal and
multilineage differentiation and maturation. In contrast,
leukemic stem cells appear to be transformed HSCs with a
loss of control of both proliferation and maturation
through accumulating genetic and epigenetic aberrations
(Huntly and Gilliland 2005). Important genetic findings in
AML comprise chromosomal translocations involving
different transcription factors and activating point muta-
tions in multiple signal transduction pathways (Tenen
2003). Furthermore, the ineffective hematopoiesis in
AML is thought to be the result of dysregulation between
the blasts and the surrounding hematopoietic microenvi-
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DOI 10.1007/s13148-011-0043-5ronment consisting of a variety of cells, including bone
marrow stromal cells and their products, especially
cytokines and extracellular matrix (ECM) molecules
(Mayani 1996). This bone marrow microenvironment
supports and regulates the proliferation and differentiation
of hematopoietic cells (Bhatia et al. 1993). However, the
role of the microenvironment itself in AML has not yet
been well characterized.
DNA methylation of CpG islands associated with gene
promoter regions is the most extensively studied epige-
netic mechanism, which is not only crucial for the
regulation of gene expression during normal mammalian
development but also contributes to silencing of cancer-
related genes in tumorigenesis (Herman and Baylin 2003;
Esteller 2008). Recent advances in the rapidly evolving
field of cancer epigenetics have shown extensive reprog-
ramming of every component of the epigenetic machinery
in cancer including DNA methylation, histone modifica-
tions, nucleosome positioning, and non-coding RNAs,
specifically microRNA expression (Sharma et al. 2010).
Additionally, epigenetic changes play an important role as
an alternative mechanism of transcriptional inactivation of
cancer-related genes in hematopoietic malignancies. These
aberrations may thus contribute to enhanced proliferation
and self-renewal, differentiation arrest as well as impaired
apoptosis of leukemic blasts (Galm et al. 2006). Patterns
of DNA methylation are non-random and tumor type
specific, and this could also be shown in AML (Figueroa
et al. 2010).
Inter-α-trypsine inhibitors (ITIs) are a family of plasma
protease inhibitors consisting of one light chain (bikunin)
and a variable set of two homologous heavy chains
(ITIH1-5) which are linked by chondroitin sulfate, a
glycosaminoglycan. ITIHs stabilize the ECM by covalently
binding to hyaluronic acid, which is a major component of
the ECM, forming so-called cable-like structures (Enghild
et al. 1991; Chen et al. 1994; Bost et al. 1998). ITIs can be
found at high concentrations in human plasma as well as in
other compartments especially in the connective tissue
(Zhuo et al. 2004). ITIs have been found to have inhibitory
effects on tumor progression and metastasis in vitro owing
to the protease inhibiting function of bikunin and the
stabilization of the ECM by the ITIHs (Kobayashi et al.
1995; Bourguignon et al. 1999). ITIH5 is a novel member
of the ITIH family and the only ITIH gene with a CpG-rich
promoter region. Aberrant DNA hypermethylation associ-
ated with transcriptional silencing of the putative tumor
suppressor gene ITIH5 has previously been found in breast
cancer and reportedly has a negative prognostic impact in
this disease (Himmelfarb et al. 2004; V eeck et al. 2008). In
this study, using a candidate gene approach, we determined
the methylation status of the promoter-associated CpG
island of ITIH5 in leukemia cell lines and primary AML
patient samples.
Table 1 Characteristics of the patient cohort
Total number of patients, n 104
Age (years, median and range) 60.4 (21.0–89.1)
Gender, n
Male 50
Female 54
Source of material, n
BM 72
PB 32
FAB subtype, n
M0 5
M1 34
M2 14
M4 27
M4eo 11
M5 12
M7 1
Karyotype, n
Favorable 16
Intermediate 60
Unfavorable 14
No data 14
Laboratory parameters (median and range)
WBC (10
9/l) 21.4 (0.9–354)
Hemoglobin (g/l) 91 (41–142)
Platelet count (10
9/l) 60.5 (3–680)
LDH (U/l) 496 (139–3761)
F AB French–American–British, WBC white blood cell, LDH lactate
dehydrogenase
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Fig. 1 Schematic representation of the human ITIH5 promoter region. Dark gray bars indicate location of the three promoter-associated CpG
islands. The bold double-headed arrow shows the region amplified by MSPMaterials and methods
Human tissue samples
After informed consent was given, bone marrow (BM) and
peripheral blood (PB) specimens (72 BM and 32 PB) were
obtained at the time of diagnosis during routine clinical
assessment of 104 patients with AML, who presented at the
University Hospital Aachen, Germany, between 1995 and
2008. Cytogenetic data were available in 90 of 104 patients.
PB samples from healthy volunteers served as controls.
Mononuclear cells from BM and PB were separated by
density gradient centrifugation prior to further analysis. The
clinical characteristics of the patient cohort are summarized
in Table 1.
Cell culture and drug treatment
We obtained the AML cell lines KG1a, HL-60, and GDM-1
as well as the Hodgkin’s lymphoma cell lines L-428, L-540,
and L-1236 from the German Collection of Microorganisms
and Cell Cultures (DSMZ, Braunschweig, Germany). Cells
were routinely cultured in RPMI 1640 (Invitrogen, Karls-
ruhe, Germany) supplemented with 10–20% fetal calf
serum (Biochrom AG, Berlin, Germany). For demethyla-
tion studies, the AML cell lines HL-60 and KG1a were
incubated with or without a final concentration of 1.0 μM
5-Aza-2′-deoxycytidine (DAC; Sigma, St. Louis, MO,
USA) for 96 h.
Sodium bisulfite treatment and methylation-specific
polymerase chain reaction
Genomic DNA was isolated from cell lines and primary
tissues using standard methods. A purification of leukemic
blasts prior to further analysis was not performed owing to
the high sensitivity of the methylation-specific polymerase
chain reaction (MSP) technique (Herman et al. 1996).
Approximately 1 μg DNA was sodium bisulfite-modified
and subjected to MSP with primers specifically recognizing
the unmethylated or the methylated sequence of the ITIH5
gene, respectively. Although MSP primers and reaction
conditions for the ITIH5 gene have been published
previously (V eeck et al. 2008), we decided to design new
primers annealing closer to the transcription start site
(Fig. 1). The primer-specific reaction temperature for MSP
was 63°C. The primer sequences used in this study are
shown in Table 2.
Statistical analysis
Overall survival curves were plotted according to the
method of Kaplan and Meier and compared using the log-
rank test. Survival was calculated from the date of
diagnosis until the patients’ death or last visit. Correlations
between variables were analyzed using the Fisher’s exact
two-sided test. A p value <0.05 was considered to be
statistically significant. All calculations were performed
using the SAS statistical software version 9.1.3 (SAS
Institute Inc., Cary, NC, USA).
Results
MSP analysis revealed that the ITIH5 promoter region was
fully hypermethylated in the AML cell lines HL-60, KG1a,
and GDM-1 as well as in the Hodgkin’s lymphoma cell
Fig. 2 Representative MSP analyses of the ITIH5 gene in cell lines
(AML: KG1a, HL-60, GDM-1; Hodgkin’s lymphoma: L-428, L-540,
L-1236). DNA from peripheral blood cells of healthy donors, in vitro
methylated DNA, and water served as controls. Lane U amplified
product with primers recognizing the unmethylated ITIH5 sequence,
lane M amplified product recognizing the methylated ITIH5 sequence
Fig. 3 Representative MSP analyses of the ITIH5 gene in AML cell
lines HL-60 and KG1a after treatment with 1 μM DAC for 96 h. DNA
from peripheral blood cells of healthy donors, in vitro methylated
DNA, and water served as controls. Lane U amplified product with
primers recognizing the unmethylated ITIH5 sequence, lane M
amplified product recognizing the methylated ITIH5 sequence
Table 2 MSP primer sequences specific for the ITIH5 promoter
region
Primer Primer sequence Amplicon
length (bp)
ITIH5 U sense G TTG GAG TTT TGG GTG TTG
TAA AGT
141
ITIH5 U antisense CCC AAC TCTACA CCT CTT
CTTACA
ITIH5 M sense TTG GAG TTT TGG GCG TTG
TAA AGC
139
ITIH5 M antisense CCA ACT CTA CGC CTC TTC
CTA CG
Clin Epigenet (2011) 2:419–423 421lines L-428, L-540, and L-1236 (Fig. 2). In the cell lines
HL-60 and KG1a, treatment with the demethylating agent
DAC for 96 h at a 1.0 μM concentration induced a partial
promoter demethylation (Fig. 3). We then analyzed the
ITIH5 methylation status in mononuclear cells obtained
from 104 patients with newly diagnosed AML. The
frequency of aberrant methylation among the primary
patient samples was 14.4% (15 of 104; Fig. 4).
Among clinical prognostic parameters, we found no
significant correlation between hypermethylation of ITIH5
and cytogenetics (Table 3), elevated serum levels of lactate
dehydrogenase, French–American–British subtype, gender,
age, peripheral blood cell counts, and overall survival (OS;
p=0.08; Fig. 5). Notably, median WBC was elevated in
patients with ITIH5 hypermethylation compared to those
without, though the difference was not statistically significant
(73.3×10
9/l vs. 49.9×10
9/l, p=0.24).
Discussion
Recent advances in the field of epigenetics have shown that
human cancer cells harbor global epigenetic abnormalities
in addition to numerous genetic alterations (Sharma et al.
2010). Among these epigenetic aberrations, DNA hyper-
methylation is the one which has been most extensively
studied. With regard to our findings, we conclude that
promoter hypermethylation of ITIH5 is a novel epigenetic
event in AML that may contribute to leukemogenesis by
interfering with the interaction between the ECM and the
leukemic clone. It has been shown that in the BM of AML
patients, the ECM is enriched in hyaluronic acid, although
the impact of this alteration still remains poorly defined
(Sundström et al. 2005). Since there was a trend toward an
association between increased WBC and ITIH5 promoter
hypermethylation, we hypothesize that epigenetic dysregu-
lation of ITIH5 may result in an impaired interaction
between the leukemic clone and its’ surrounding ECM in
the BM. This may potentially lead to either increased
peripheral WBC or a higher turnover of leukemic cells.
Additionally, the OS curve implies a slight advantage for
patients who carry a hypermethylated ITIH5 promoter
region, though this difference was not statistically signifi-
cant. However, since little is known about the interaction
between leukemic blasts and their surrounding ECM,
further studies are required to better understand the
functional consequences and the impact of a dysregulation
of the blast–matrix interaction on the pathogenesis and the
course of AML as well as the function of ITIH5 in this
setting. Additionally, our cell line data indicate that
epigenetic dysregulation of ITIH5 may also play a role in
the pathogenesis of Hodgkin’s lymphoma.
Epigenetic silencing of cancer-related genes has been
shown to be reversible. Consequently, epigenetic alterations
are potential targets of great interest for a molecular
targeted therapy in human malignancies (Gilbert et al.
2004). In this study, we have shown that treatment of the
AML cell lines KG1a and HL-60 with the demethylating
agent DAC resulted in partial demethylation of the ITIH5
promoter region thus allowing the restoration of a poten-
Fig. 4 Representative MSP analyses of the ITIH5 gene in primary
AML patient samples. DNA from peripheral blood cells of healthy
donors, in vitro methylated DNA, and water served as controls. Lane
U amplified product with primers recognizing the unmethylated ITIH5
sequence, lane M amplified product recognizing the methylated ITIH5
sequence
Table 3 Association between the ITIH5 methylation status and
cytogenetic findings in the patient cohort
Cytogenetic risk ITIH5 hypermethylation (%)
Total number of patients (n=104) 14.4% (15/104)
Favorable risk (n=16) 18.8% (3/16)
inv(16) (n=11) 27.3% (3/11)
t(8;21) (n=5) 0%
Intermediate risk (n=60) 11.7% (7/60)
Unfavorable risk (n=14) 7.1% (1/14)
Karyotype n.a. (n=14) 28.6% (4/14)
n.a. not available
Fig. 5 Survival curves of patients with primary AML according to the
ITIH5methylation statusatdiagnosis(p=0.08). In a total of 104 patients
analyzed, 15 showed aberrant ITIH5 promoter hypermethylation
422 Clin Epigenet (2011) 2:419–423tially silenced gene expression. The use of the demethylat-
ing agents 5-azacytidine and DAC has already been
approved for the treatment of myelodysplastic syndromes
(Kantarjian et al. 2006). The partial reversal of the ITIH5
promoter hypermethylation may contribute to the beneficial
effect of an epigenetically targeted therapy in AML. Further
studies are warranted to assess the impact of ITIH5
promoter hypermethylation on ITIH5 expression levels.
Since our patient cohort only consisted of 104 patient
samples and was heterogeneous for age, risk factors, and
treatment regimens, no definitive conclusion can be retained
from these data regarding the prognostic impact of ITIH5
promoterhypermethylation.Therefore,the analysisofa larger
numberofwell-characterizedpatientsamplesmaybeusefulto
further clarify the possible role of aberrant ITIH5 methylation
as a biomarker in AML. Consequently, additional studies are
necessary to elucidate the functional role of epigenetic
dysregulation of ITIH5 in leukemogenesis.
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